Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-term Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)

Trial Profile

A Long-term Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Parathyroid hormone (Primary)
  • Indications Hypoparathyroidism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RACE
  • Sponsors NPS Pharmaceuticals; Shire
  • Most Recent Events

    • 01 Aug 2019 Results of 5-year interim analysis, published in the Journal of Clinical Endocrinology and Metabolism
    • 15 May 2019 According to a Takeda media release, data from the study will be presented at the upcoming European Congress of Endocrinology (ECE) Annual Meeting 2019.
    • 26 Mar 2019 Results published in the Takeda Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top